On April 27, 2021 Guardant Health, Inc. (Nasdaq: GH) reported a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic for Enhertu (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody-drug conjugate (ADC), being studied in the treatment of patients with advanced metastatic non-small cell lung cancer (NSCLC) (Press release, Guardant Health, APR 27, 2021, https://www.businesswire.com/news/home/20210427005136/en/Guardant-Health-Announces-Collaboration-With-Daiichi-Sankyo-to-Develop-Guardant360%C2%AE-CDx-as-a-Companion-Diagnostic-for-Enhertu%C2%AE-in-Advanced-Metastatic-Non-Small-Cell-Lung-Cancer [SID1234578580]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For patients with metastatic non-small cell lung cancer, personalized medicines targeting actionable mutations, as revealed by our Guardant360 liquid biopsy test, have been life-changing," said Helmy Eltoukhy, Guardant Health CEO. "Such medicines may extend overall survival for many patients, and we are excited to work with Daiichi Sankyo, as there remains an unmet medical need to help non-small cell lung cancer patients with HER2 mutations."

The Guardant360 CDx test is FDA-approved to provide comprehensive genomic profiling results to guide treatment in all solid tumors, including NSCLC. Sequencing a broad number of genes to understand the molecular drivers of a patient’s cancer is critical, as the number of treatment-relevant genomic alterations continues to grow.